Prostate Cancer

An expert explains the significance of the recent approval of Xtandi for non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR) by the Food and Drug Administration.

Researchers have found that a deeper look at proteins and cells may help explain why prostate cancer tumors often become resistant to hormone therapy.

The first patient has received TLX591, an antibody-based treatment for PSMA-positive metastatic castrate-resistant prostate cancer.

I see a psychologist who is helping me to understand my feelings and to learn mindfulness meditation techniques.

In honor of Men’s Health Awareness Month, CURE® looked back on some of the most significant news within the oncology space.

The Food and Drug Administration approved six new cancer therapies in November 2023.

The Food and Drug Administration approved Xtandi for non-metastatic castration-sensitive prostate cancer at high risk for biochemical recurrence.

My diagnosis of prostate cancer gave me an unsuspected gift.

I was in denial after the shock of being told I had prostate cancer.

Patients with prostate cancer who receive docetaxel with standard-of-care treatment may have a reduced risk of death and an improved prognosis, according to a recent study.

A phase 3 trial found that testosterone recovery after androgen deprivation therapy leads to better quality of life following high-risk prostate cancer.

Recent research has put a spotlight on a number of factors which could be used to estimate which patients with nonmetastatic, unfavorable-risk prostate cancer are at high risk for a shorter time until PSA recurrence and failure.

Prostatic urethra length may help predict which patients with prostate cancer are more likely to experience chronic urinary side effects after radiation treatment, according to a recent study.

According to the Food and Drug Administration, the shortage of Novartis’ prostate cancer treatment Pluvicto, which began in March, has been resolved, with the manufacturer expecting a continued expansion of supply.

Data presented at ESMO “provides strong evidence for an enhanced anti-cancer effect with the combination” of Pluvicto and Xtandi, according to one expert.

Reginald Tucker-Seeley, MA, ScM, ScD, concludes the program with advice for caregivers and patients with prostate cancer to maximize the benefit of treatment.

Alicia Morgans, MD, MPH, offers advice to patients newly diagnosed with prostate cancer and reviews educational resources available for patients and their caregivers.

Practical advice for improving clinical trials to ensure they are more reflective of the overall population of patients with prostate cancer.

Rashid K. Sayyid, MD, MSc, discusses the role of combination therapy in metastatic castrate-resistant prostate cancer.

Patients with metastatic castration-resistant prostate cancer who were never treated with a taxane derived a progression-free survival benefit from treatment with Pluvicto.

The addition of Keytruda to Xtandi showed no improvements for radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer.

As Susan Sullivan discussed her lung cancer diagnosis and the FDA discusses banning specific hair straightening products due to long-term health effects, here’s what’s happening in the oncology space this week.

Rashid K. Sayyid, MD, MSc, gives a brief overview of treatment options for nonmetastatic castrate-resistant prostate cancer.

Expert perspectives on the treatment approach for patients with metastatic castrate-resistant prostate cancer.